Gene · 3702
Papers2,789
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,789
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Protocol for a randomized control trial of the Building Regulation in Dual Generations Program (BRIDGE): preventing the intergenerational transmission of mental illness in at-risk preschool children. | Trials | 2023 | 37726821 | PubTator, text mining | PubMed |
| PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. | Nat Cancer | 2023 | 37723306 | PubTator, text mining | PubMed |
| Early Immune Changes Support Signet Ring Cell Dormancy in CDH1-Driven Hereditary Diffuse Gastric Carcinogenesis. | Mol Cancer Res | 2023 | 37707375 | PubTator, text mining | PubMed |
| Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race-specific luminal-basal and microenvironmental differences. | Cancer Commun (Lond) | 2023 | 37700560 | PubTator, text mining | PubMed |
| Zanubrutinib: past, present, and future. | Blood Cancer J | 2023 | 37696810 | PubTator, text mining | PubMed |
| Methylation-related genes involved in renal carcinoma progression. | Front Genet | 2023 | 37693315 | PubTator, text mining | PubMed |
| [Gastrointestinal stromal tumors: a retrospective study]. | Pan Afr Med J | 2023 | 37692978 | PubTator, text mining | PubMed |
| Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia. | J Hematol | 2023 | 37692865 | PubTator, text mining | PubMed |
| PI3K signaling through a biochemical systems lens. | J Biol Chem | 2023 | 37673340 | PubTator, text mining | PubMed |
| Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. | J Hematol Oncol | 2023 | 37670328 | PubTator, text mining | PubMed |
| Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation. | PLoS Pathog | 2023 | 37669313 | PubTator, text mining | PubMed |
| Predicting the target landscape of kinase inhibitors using 3D convolutional neural networks. | PLoS Comput Biol | 2023 | 37669273 | PubTator, text mining | PubMed |
| Overexpression of CD2/CD27 could inhibit the activation of nitrogen metabolism pathways and suppress M2 polarization of macrophages, thereby preventing brain metastasis of breast cancer. | Transl Oncol | 2023 | 37666207 | PubTator, text mining | PubMed |
| Transcriptomic and proteomic assessment of tocilizumab response in a randomized controlled trial of patients hospitalized with COVID-19. | iScience | 2023 | 37664617 | PubTator, text mining | PubMed |
| GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights. | Front Oncol | 2023 | 37664031 | PubTator, text mining | PubMed |
| Metabolic signature and proteasome activity controls synovial migration of CDC42hiCD14+ cells in rheumatoid arthritis. | Front Immunol | 2023 | 37662900 | PubTator, text mining | PubMed |
| Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib. | PLoS One | 2023 | 37651403 | PubTator, text mining | PubMed |
| A novel UHPLC‒MS/MS method for quantitative analysis of zanubrutinib in rat plasma: application to an in vivo interaction study between zanubrutinib and triazole antifungal. | BMC Chem | 2023 | 37649082 | PubTator, text mining | PubMed |
| Overexpression of Bruton Tyrosine Kinase Inhibits the Proliferation, Migration, and Invasion of Non-Small Cell Lung Cancer Cells. | Anal Cell Pathol (Amst) | 2023 | 37638060 | PubTator, text mining | PubMed |
| Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. | Molecules | 2023 | 37630287 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3702/papers?page=12